Table 1 Patient demographics and stimulation parameters are summarized

From: Randomized crossover trial on motor and non-motor outcome of directional deep brain stimulation in Parkinson’s disease

ID

Sex/gender

Age (years)

Disease duration (years)

LEED (mg/d)

Stimulation parameters Omnidirectional

Stimulation parameters Directional

1

m

65

10

1125

L 3− G+ 2.1 mA 60 µs 130 Hz

R 11− G+ 3.7 mA 60 µs 130 Hz

L 3C− G+ 1.4 mA 60 µs 130 Hz

R 11B− G+ 2.3 mA 60 µs 130 Hz

2*

f

61

15

869

L 3− G+ 3.3 mA 60 µs 130 Hz

R 11− G+ 3.5 mA 60 µs 130 Hz

L 3A− G+ 2.5 mA 60 µs 130 Hz

R 11C− G+ 2.5 mA 60 µs 130 Hz

3

m

58

11

1250

L 3− G+ 1.3 mA 60 µs 130 Hz

R 11− G+ 2.3 mA 60 µs 130 Hz

L 3C− G+ 0.5 mA 60 µs 130 Hz

R 11A− G+ 1.2 mA 60 µs 130 Hz

4*

m

71

15

450

L 3− G+ 2.70 mA 60 µs 130 Hz

R 11− G+ 2.20 mA 60 µs 130 Hz

L 3A− G+ 2.2 mA 60 µs 130 Hz

R 11A− G+ 2.0 mA 60 µs 130 Hz

5

m

58

9

1205

L 3− G+ 1.5 mA 60 µs 130 Hz

R 11− G+ 1.5 mA 60 µs 130 Hz

L 3A− G+ 0.95 mA 60 µs 130 Hz

R 11C− G+ 1.05 mA 60 µs 130 Hz

6

m

56

6

1293

L 3− G+ 0.8 mA 60 µs 130 Hz

R 11− G+ 4.5 mA 60 µs 130 Hz

L 3A− G+ 0.55 mA 60 µs 130Hz

R 11A− G+ 3.1 mA 60 µs 130 Hz

7

m

46

11

1265

L 3− G+ 1.6 mA 60 µs 130 Hz

R 11− G+ 3.7 mA 60 µs 130 Hz

L 3A− G+ 1.25 mA 60 µs 130 Hz

R 11B− G+ 2.85 mA 60 µs 130 Hz

8*

f

68

12

815

L 3− G+ 2.2 mA 60 µs 130 Hz

R 11− G+ 4.0 mA 60 µs 130 Hz

L 3A− G+ 1.8 mA 60 µs 130Hz

R 11C− G+ 2.7 mA 60 µs 130 Hz

9

f

53

14

375

L 3− G+ 2.8 mA 60 µs 130 Hz

R 11− G+ 2.9 mA 60 µs 130 Hz

L 3A− G+ 2.05 mA 60 µs 130 Hz

R 11B− G+ 1.95 mA 60 µs 130 Hz

10

f

75

13

725

L 3− G+ 4.7 mA 60 µs 130 Hz

R 11− G+ 4.7 mA 60 µs 130 Hz

L 3B− G+ 3.35 mA 60 µs 130Hz

R 11B− G+ 3.35 mA 60 µs 130 Hz

11

f

59

18

525

L 3− G+ 1.1 mA 60 µs 130 Hz

R 11− G+ 1.5 mA 60 µs 130 Hz

L 3B− G+ 0.75 mA 60 µs 130Hz

R 11C− G+ 1.00 mA 60 µs 130 Hz

12

m

61

6

441

L 3− G+ 2.7 mA 60 µs 130 Hz

R 11− G+ 2.8 mA 60 µs 130 Hz

L 3C− G+ 2.6 mA 60 µs 130 Hz

R 11A− G+ 1.95 mA 60 µs 130 Hz

13

m

73

10

1033

L 3− G+ 2.5 mA 60 µs 130 Hz

R 11− G+ 2.7 mA 60 µs 130 Hz

L 3B− G+ 1.7 mA 60 µs 130 Hz

R 11B− G+ 1.85 mA 60 µs 130 Hz

14

m

71

8

875

L 3− G+ 3.0 mA 60 µs 130 Hz

R 11− G+ 2.8 mA 60 µs 130 Hz

L 3C− G+ 2.1 mA 60 µs 130 Hz

R 11A− G+ 1.8 mA 60 µs 130 Hz

15

m

67

12

815

L 2− G+ 1.7 mA 60 µs 130 Hz

R 10− G+ 2.2 mA 60 µs 130 Hz

L 2C− G+ 1.1 mA 60 µs 130 Hz

R 10B− G+ 1.4 mA 60 µs 130 Hz

16

m

67

18

960

L 3− G+ 2.8 mA 60 µs 130 Hz

R 11- G + 3.3 mA 60 µs 130 Hz

L 3B− G+ 2.1 mA 60 µs 130 Hz

R 11B− G+ 2.3 mA 60 µs 130 Hz

17

f

52

8

708

L 3− G+ 2.3 mA 60 µs 130 Hz

R 11− G+ 2.1 mA 60 µs 130 Hz

L 3C− G+ 1.65 mA 60 µs 130Hz

R 11C− G+ 1.5 mA 60 µs 130 Hz

18

m

50

9

859

L 3− G+ 2.7 mA 60 µs 130 Hz

R 11− G+ 0.9 mA 60 µs 130 Hz

L 3A− G+ 1.9 mA 60 µs 130Hz

R 11B− G+ 0.5 mA 60 µs 130 Hz

19

m

67

13

1050

L 3− G+ 2.7 mA 60 µs 130 Hz

R 11− G+ 2.5 mA 60 µs 130 Hz

L 3C− G+ 1.8 mA 60 µs 130 Hz

R 11C− G+ 1.7 mA 60 µs 130 Hz

  1. LEED levodopa equivalent dose during the cross-over phase.
  2. The asterisk “*” indicates patients in whom a reprogramming was necessary during the cross-over phase: ID2: the calculated directional stimulation was L 3A− G+ 2.1 mA 60 µs 130 Hz, R 11C− G+ 2.2 mA 60 µs 130 Hz; patient reported bradykinesia and had rigidity and freezing of gait with directional stimulation during the cross-over-phase so that we needed to increase the stimulation Intensity ID4: the calculated directional stimulation was L 3A− G+ 1.85 mA 60 µs 130 Hz, R 11A− G+ 1.55 mA 60 µs 130 Hz; patient reported bradykinesia and had rigidity with directional stimulation during the cross-over-phase so that we needed to increase the stimulation intensity. ID8: the calculated directional stimulation was L 3A− G+ 1.6 mA 60 µs 130 Hz, R 11C− G+ 2.6 mA 60 µs 130 Hz; patient reported worsening of motor fluctuations so that we needed to increase the stimulation intensity.
Back to article page